DAFNA Capital Management’s Immune Design Corp. IMDZ Stock Holding History

DAFNA Capital Management’s Portfolio IMDZ Stock Details IMDZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-328,500	Closed	-$1.13M	–	87
2018 Q3	$1.13M	Hold	328,500	–	–	0.47%	49
2018 Q2	$1.5M	Hold	328,500	–	–	0.7%	40
2018 Q1	$1.08M	Hold	328,500	–	–	0.53%	51
2017 Q4	$1.28M	Buy	+328,500	New	+$1.79M	0.69%	43
2016 Q4	–	Sell	-40,000	Closed	-$303K	–	84
2016 Q3	$303K	Buy	+40,000	New	+$292K	0.21%	61

Other funds holding IMDZ

Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCPEM

Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

DAFNA Capital Management's IMDZ Position: Q4 2018 in Review

DAFNA Capital Management sold out of Immune Design Corp. (IMDZ) in Q4 2018, closing a stake of 328,500 shares — an estimated $1.13M sold.

DAFNA Capital Management first reported a position in IMDZ in Q3 2016 and held it in 5 quarters. The position peaked at $1.5M in Q2 2018. 64 funds tracked by Wall St. Rank hold IMDZ as of Q4 2018.

DAFNA Capital Management reported no remaining Immune Design Corp. position as of Q4 2018 after selling out during the quarter.
DAFNA Capital Management sold 328,500 Immune Design Corp. shares in Q4 2018, an estimated $1.13M.
DAFNA Capital Management first reported a position in Immune Design Corp. in Q3 2016 and held it in 5 quarters.
DAFNA Capital Management's Immune Design Corp. position peaked at $1.5M in Q2 2018.
64 funds tracked by Wall St. Rank held Immune Design Corp. as of Q4 2018.

Based on DAFNA Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.